Verenium Corp (NASDAQ:VRNM)
| 2.23 Data as of May 23 |  +0.04 / +1.83%Today’s Change | 2.05 Today|||52-Week Range 4.69 | +3.24% Year-to-Date |
Latest VRNM News | Press Releases
No recent news for Verenium Corp.
Today’s Trading
| Previous close | 2.19 |
| Today’s open | 2.14 |
| Day’s range | 2.14 - 2.28 |
| Volume | 5,294 |
| Average volume (3 months) | 15,933 |
| Market cap | $28.0M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/23/2013
Growth & Valuation
| Earnings growth (last year) | +243.90% |
| Earnings growth (this year) | -208.74% |
| Earnings growth (next 5 years) | +18.00% |
| Revenue growth (last year) | -6.69% |
| P/E ratio | NM |
| Price/Sales | 0.48 |
| Price/Book | 0.91 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BPAXBioSante Pharmaceuti... | +0.01 | +0.88% |
| --Response Biomedical ... | 0.00 | 0.00% |
| GOGCGlobal Green Inc | -0.00 | -6.98% |
| ROSGRosetta Genomics Ltd | +0.05 | +1.27% |
Data as of 4:00pm ET, 05/23/2013
Financials
| Next reporting date | August 12, 2013 |
| EPS forecast (this quarter) | -$0.27 |
| Annual revenue (last year) | $57.2M |
| Annual profit (last year) | $18.2M |
| Net profit margin | 31.96% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director James E. Levine, MBA |
Chief Operating Officer & Executive Vice President Janet S. Roemer, MBA |
Corporate headquarters San Diego, California |
Forecasts
